AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34711598 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG vaccination
Number of subjects: 10078
Study 34711598 — intervention group
Group type: COMPARATOR
Intervention: No BCG vaccination (control group)
Number of subjects: 10078
Study 34711639 — intervention group
Group type: EXPERIMENTAL
Intervention: PPGR prediction model
Number of subjects: 121
Study 34711639 — intervention group
Group type: COMPARATOR
Intervention: Baseline model (standard of care)
Number of subjects: 121
Study 34711663 — intervention group
Group type: EXPERIMENTAL
Intervention: Peptide vaccination targeting mutated Gsα
Number of subjects: 25
Study 34711663 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of peptide vaccination with immune checkpoint inhibition
Number of subjects: 25
Study 34711661 — intervention group
Group type: EXPERIMENTAL
Intervention: PPCI during the pandemic (2020)
Number of subjects: 16674
Study 34711938 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (iNO) for 24-96 hours during the first 0-7 days after birth
Number of subjects: 140
Study 34711938 — intervention group
Group type: COMPARATOR
Intervention: Inhaled nitric oxide (iNO)
Number of subjects: 140
Study 34712113 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesenchymal stromal cells (MSCs) administered through the internal carotid arteries
Number of subjects: 7
Study 34712117 — intervention group
Group type: EXPERIMENTAL
Intervention: Retinal oxygen metabolism assessment in RMS patients
Number of subjects: 16
Study 34712117 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (HC)
Number of subjects: 16
Study 34712229 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Dose Radiation Therapy (LDRT) with a single dose per fraction of 0.5Gy
Number of subjects: 125
Study 34712229 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Dose Radiation Therapy (LDRT)
Number of subjects: 125
Study 34712513 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant treatment with intravenous PD-1 inhibitor toripalimab (240 mg), carboplatin (AUC 5), and pemetrexed (500 mg/m2) for three cycles.
Number of subjects: 0
Study 34712714 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 0
Study 34712893 — intervention group
Group type: EXPERIMENTAL
Intervention: Human milk nutrient concentrations (micronutrients)
Number of subjects: 0
Study 34712928 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct-acting antivirals (DAAs) - sofosbuvir with an NS5A inhibitor (ledipasvir, daclatasvir or velpatasvir)±ribavirin
Number of subjects: 3477
Study 34712959 — intervention group
Group type: EXPERIMENTAL
Intervention: Endocrine therapy (letrozole) combined with CDK inhibitor ribociclib
Number of subjects: 0
Study 34712959 — intervention group
Group type: COMPARATOR
Intervention: Endocrine therapy (letrozole) alone
Number of subjects: 0
Study 34713017 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet Cognitive Behavioral Therapy with additional face-to-face outpatient psychotherapy (ICBT+)
Number of subjects: 168
Study 34713017 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet Cognitive Behavioral Therapy without additional face-to-face outpatient psychotherapy (ICBT)
Number of subjects: 168
Study 34713023 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital technology-based lifestyle-integrated exercise intervention
Number of subjects: 0
Study 34713023 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 34713030 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 34713106 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 34713152 — intervention group
Group type: EXPERIMENTAL
Intervention: Human Papillomavirus Vaccination
Number of subjects: 0
Study 34713152 — intervention group
Group type: EXPERIMENTAL
Intervention: Social Media Intervention
Number of subjects: 0
Study 34713152 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 34713183 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based conversational engagement
Number of subjects: 0
Study 34713183 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 34713337 — intervention group
Group type: EXPERIMENTAL
Intervention: Type QM-C hysterectomy
Number of subjects: 181
Study 34713396 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased PBR5-25 (marker of glycocalyx integrity)
Number of subjects: 600
Study 34713396 — intervention group
Group type: EXPERIMENTAL
Intervention: PBR5-25
Number of subjects: 600
Study 34713614 — intervention group
Group type: EXPERIMENTAL
Intervention: 3MC (ART provided three-monthly in community ART groups)
Number of subjects: 599
Study 34713614 — intervention group
Group type: EXPERIMENTAL
Intervention: 6MC (ART provided six-monthly in either CAGs or at community-distribution points)
Number of subjects: 599
Study 34713614 — intervention group
Group type: COMPARATOR
Intervention: SoC (Standard-of-care three-monthly ART provision at healthcare facilities)
Number of subjects: 599
Study 34713614 — intervention group
Group type: EXPERIMENTAL
Intervention: 3MC
Number of subjects: 599
Study 34713614 — intervention group
Group type: EXPERIMENTAL
Intervention: 6MC
Number of subjects: 599
Study 34713711 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle modification program
Number of subjects: 0
Study 34713738 — intervention group
Group type: EXPERIMENTAL
Intervention: Nondirected uterus donation
Number of subjects: 44
Study 34713745 — intervention group
Group type: EXPERIMENTAL
Intervention: BNT162b2 vaccination
Number of subjects: 88
Study 34713782 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin treatment in patients with ischemic heart disease (IHD)
Number of subjects: 5808
Study 34713782 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitors (ACEI)/angiotensin receptor antagonists in patients with IHD, arterial hypertension, chronic heart failure (CHF), and atrial fibrillation
Number of subjects: 5808
Study 34713782 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blockers in patients with IHD, arterial hypertension, chronic heart failure (CHF), and atrial fibrillation
Number of subjects: 5808
Study 34713782 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral anticoagulants (OAC), primarily direct OAC, clopidogrel/prasugrel/ticagrelor in patients with IHD
Number of subjects: 5808
Study 34713782 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral antihyperglycemic therapy in patients with type 2 diabetes mellitus (DM)
Number of subjects: 5808
Study 34713782 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting insulins in patients with type 1 DM
Number of subjects: 5808
Study 34713782 — intervention group
Group type: COMPARATOR
Intervention: Spironolactone treatment in patients with CHF
Number of subjects: 5808
Study 34713782 — intervention group
Group type: COMPARATOR
Intervention: Inhaled corticosteroids (iCS) in patients with chronic obstructive pulmonary disease (COPD)
Number of subjects: 5808
Study 34713932 — intervention group
Group type: EXPERIMENTAL
Intervention: Diffusion Tensor Imaging (DTI)
Number of subjects: 30
Study 34714159 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 34714423 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated pretreatment CEA
Number of subjects: 788
Study 34714423 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated pretreatment CA 19-9
Number of subjects: 788
Study 34714423 — intervention group
Group type: COMPARATOR
Intervention: Patients without elevated tumor markers
Number of subjects: 788
Study 34714423 — intervention group
Group type: COMPARATOR
Intervention: Patients with either elevated CEA or CA 19-9
Number of subjects: 788
Study 34714423 — intervention group
Group type: COMPARATOR
Intervention: Patients with both elevated CEA and CA 19-9
Number of subjects: 788
Study 34714423 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative presence of ctDNA
Number of subjects: 788
Study 34714450 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune checkpoint inhibitors (ICI) combined with radiation therapy (RT)
Number of subjects: 0
Study 34714450 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune checkpoint inhibitors (ICI) combined with cryotherapy
Number of subjects: 0
Study 34714450 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of ICI with RT and cryotherapy
Number of subjects: 0
Study 34714450 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized phase II studies (P-RAD and ipilimumab/nivolumab/cryoablation)
Number of subjects: 0
Study 34714527 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab 300 mg weekly
Number of subjects: 2677
Study 34714555 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomalidomide plus low-dose dexamethasone (POM/DEX)
Number of subjects: 151
Study 34714558 — intervention group
Group type: EXPERIMENTAL
Intervention: Prognostic radiomics score (RS) derived from PET radiomics features
Number of subjects: 133
Study 34714708 — intervention group
Group type: EXPERIMENTAL
Intervention: Craniospinal RT dose of 23.4 Gy for average-risk patients and 36-39.6 Gy for high-risk patients, boost dose of 55.8 Gy to the tumor bed.
Number of subjects: 124
Study 34714708 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing RT dose to the corpus callosum (CC) or frontal white matter (WM) and hippocampus.
Number of subjects: 124
Study 34714976 — intervention group
Group type: COMPARATOR
Intervention: PROPEL usual care
Number of subjects: 2210
Study 34714976 — intervention group
Group type: EXPERIMENTAL
Intervention: REPOWER in-clinic individual visits
Number of subjects: 2210
Study 34714976 — intervention group
Group type: EXPERIMENTAL
Intervention: REPOWER telephone group visits
Number of subjects: 2210
Study 34714976 — intervention group
Group type: EXPERIMENTAL
Intervention: REPOWER in-clinic group visits
Number of subjects: 2210
Study 34714976 — intervention group
Group type: EXPERIMENTAL
Intervention: PROPEL in-clinic and telephone visits
Number of subjects: 2210
Study 34715884 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet soluble (s)CD40L
Number of subjects: 0
Study 34715884 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet soluble (s)CD62P
Number of subjects: 0
Study 34715906 — intervention group
Group type: EXPERIMENTAL
Intervention: Organizational Skills Training (OST)
Number of subjects: 142
Study 34715906 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 142
Study 34716161 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified downregulation with GnRH analogue for 6 weeks
Number of subjects: 162
Study 34716161 — intervention group
Group type: COMPARATOR
Intervention: Standard downregulation with GnRH analogue for 1 week
Number of subjects: 162
Study 34716177 — intervention group
Group type: EXPERIMENTAL
Intervention: Adavosertib 300 mg daily on days 1 through 5 and 8 through 12 of a 21-day cycle
Number of subjects: 120
Study 34716196 — intervention group
Group type: EXPERIMENTAL
Intervention: Pexidartinib
Number of subjects: 91
Study 34716198 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab (1 mg/kg i.v. every 6 weeks) plus Nivolumab (240 mg i.v. every 2 weeks)
Number of subjects: 17
Study 34716199 — intervention group
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Number of subjects: 70
Study 34716216 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatic alterations in PKD1 or PKD2
Number of subjects: 24
Study 34716216 — intervention group
Group type: EXPERIMENTAL
Intervention: Short mutations in PKD1 or PKD2
Number of subjects: 24
Study 34716216 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatic chromosomal loss of heterozygosity (LOH) events
Number of subjects: 24
Study 34716565 — intervention group
Group type: COMPARATOR
Intervention: Oral BI 425809 25 mg (single dose) on day 1; multiple doses of itraconazole or rifampicin combined with a single dose of oral BI 425809 25 mg on day 4/7.
Number of subjects: 0
Study 34716565 — intervention group
Group type: COMPARATOR
Intervention: Oral BI 425809 25 mg (single dose) on day 1; multiple doses of rifampicin combined with a single dose of oral BI 425809 25 mg on day 4/7.
Number of subjects: 0
Study 34716570 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial fibrillation (AF) patients
Number of subjects: 808
Study 34716570 — intervention group
Group type: COMPARATOR
Intervention: Non-AF patients
Number of subjects: 808
Study 34716759 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 0
Study 34716759 — intervention group
Group type: EXPERIMENTAL
Intervention: OR-1896 (active metabolite of Levosimendan)
Number of subjects: 0
Study 34716790 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemp meal
Number of subjects: 10
Study 34716790 — intervention group
Group type: EXPERIMENTAL
Intervention: Buckwheat meal
Number of subjects: 10
Study 34716790 — intervention group
Group type: COMPARATOR
Intervention: Meat meal (beef)
Number of subjects: 10
Study 34716838 — intervention group
Group type: EXPERIMENTAL
Intervention: Synchronous pathway
Number of subjects: 125
Study 34716838 — intervention group
Group type: COMPARATOR
Intervention: Staged pathway
Number of subjects: 125
Study 34716838 — intervention group
Group type: COMPARATOR
Intervention: Staged surgery
Number of subjects: 125
Study 34716838 — intervention group
Group type: EXPERIMENTAL
Intervention: Synchronous surgery
Number of subjects: 125
Study 34716838 — intervention group
Group type: EXPERIMENTAL
Intervention: Both pathways
Number of subjects: 125
Study 34716838 — intervention group
Group type: EXPERIMENTAL
Intervention: All surgical groups
Number of subjects: 125
Study 34716965 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided conventional radiofrequency (RF) treatment of the genicular nerves
Number of subjects: 59
Study 34717057 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum anti-Müllerian hormone (AMH) levels measured using the Elecsys AMH Plus immunoassay
Number of subjects: 47
Study 34717097 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive mechanical ventilation (IMV)
Number of subjects: 178
Study 34717300 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI classification (underweight, normal, overweight)
Number of subjects: 247
Study 34717300 — intervention group
Group type: EXPERIMENTAL
Intervention: FIM gain
Number of subjects: 247
Study 34717300 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI change from admission to discharge
Number of subjects: 247
Study 34717553 — intervention group
Group type: EXPERIMENTAL
Intervention: Germline DNA self-sampling using saliva sampling kits sent by postal mail
Number of subjects: 928
Study 34717553 — intervention group
Group type: COMPARATOR
Intervention: Written reminders
Number of subjects: 928
Study 34717553 — intervention group
Group type: COMPARATOR
Intervention: Demographic and clinical factors
Number of subjects: 928
Study 34717578 — intervention group
Group type: EXPERIMENTAL
Intervention: Human milk oligosaccharides (HMO)
Number of subjects: 143
Study 34717578 — intervention group
Group type: EXPERIMENTAL
Intervention: 2'-fucosyllactose (2'FL)
Number of subjects: 143
Study 34717578 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal age
Number of subjects: 143
Study 34717578 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestational age
Number of subjects: 143
Study 34717578 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-pregnancy BMI
Number of subjects: 143
Study 34717578 — intervention group
Group type: EXPERIMENTAL
Intervention: Children of non-secretors
Number of subjects: 143
Study 34717585 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolus-tracking II (BT II)
Number of subjects: 141
Study 34717585 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolus-tracking I (BT I)
Number of subjects: 141
Study 34717585 — intervention group
Group type: EXPERIMENTAL
Intervention: Test bolus II (TB II)
Number of subjects: 141
Study 34717585 — intervention group
Group type: EXPERIMENTAL
Intervention: Test bolus I (TB I)
Number of subjects: 141
Study 34717585 — intervention group
Group type: COMPARATOR
Intervention: Traditional groups
Number of subjects: 141
Study 34717585 — intervention group
Group type: COMPARATOR
Intervention: Traditional aorta scan group
Number of subjects: 141
Study 34717606 — intervention group
Group type: EXPERIMENTAL
Intervention: IFAB questionnaire (10-item)
Number of subjects: 150
Study 34717606 — intervention group
Group type: EXPERIMENTAL
Intervention: IPAQ-S questionnaire
Number of subjects: 150
Study 34717606 — intervention group
Group type: EXPERIMENTAL
Intervention: Stages of behaviour change
Number of subjects: 150
Study 34717606 — intervention group
Group type: COMPARATOR
Intervention: Steps per day (collected by smartphone)
Number of subjects: 150
Study 34717608 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-ablative radiofrequency (RF) treatment (41°C) for five sessions with one week intervals
Number of subjects: 11
Study 34717616 — intervention group
Group type: EXPERIMENTAL
Intervention: EHR-based insurance support tool
Number of subjects: 46
Study 34717627 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediabetes
Number of subjects: 4212
Study 34717627 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes
Number of subjects: 4212
Study 34717627 — intervention group
Group type: COMPARATOR
Intervention: Normoglycemia
Number of subjects: 4212
Study 34717717 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy plus chemoradiotherapy (experimental group)
Number of subjects: 378
Study 34717717 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant chemotherapy alone (control group)
Number of subjects: 378
Study 34717726 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic Sleeve Gastroplasty (ESG)
Number of subjects: 30
Study 34717726 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic Sleeve Gastrectomy (LSG)
Number of subjects: 30
Study 34717736 — intervention group
Group type: EXPERIMENTAL
Intervention: Bridge clinic referral
Number of subjects: 0
Study 34717736 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 34717797 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy (≤5 fractions with ≥7 Gy per fraction) or hypofractionated intensity-modulated radiotherapy (60-70 Gy in ten fractions or 52.5-67.5 Gy in 15 fractions) to all lesions.
Number of subjects: 30
Study 34717922 — intervention group
Group type: EXPERIMENTAL
Intervention: miR-338-5p expression
Number of subjects: 43
Study 34717922 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette smoking history
Number of subjects: 43
Study 34718191 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe TBI individuals
Number of subjects: 22
Study 34718191 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (HCs)
Number of subjects: 22
Study 34718191 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe TBI individuals with GOSE 3-5
Number of subjects: 22
Study 34718191 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline DTI imaging
Number of subjects: 22
Study 34718447 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral treprostinil for 1 year
Number of subjects: 12
Study 34718493 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin (INR: 2-2.5) and Aspirin (withheld after first bleeding episode)
Number of subjects: 53
Study 34718493 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-implant vWf:Ag and vWf:CB
Number of subjects: 53
Study 34718493 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathological vWf:CB/vWf:Ag ratio (<0.7)
Number of subjects: 53
Study 34718493 — intervention group
Group type: EXPERIMENTAL
Intervention: vWf:CB in bleeders vs non-bleeders at t2
Number of subjects: 53
Study 34718493 — intervention group
Group type: EXPERIMENTAL
Intervention: vWf:CB/vWf:Ag ratio in bleeders vs non-bleeders at t2
Number of subjects: 53
Study 34718493 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin discontinuation
Number of subjects: 53
Study 34718501 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment for post-infarction PMR with mitral valve replacement and concomitant coronary artery bypass grafting (CABG) in 57% of cases.
Number of subjects: 214
Study 34718501 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment for post-infarction PMR.
Number of subjects: 214
Study 34718501 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment for post-infarction PMR with concomitant CABG.
Number of subjects: 214
Study 34718501 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative chronic kidney dysfunction, cardiac arrest, and cardiopulmonary bypass duration as risk factors.
Number of subjects: 214
Study 34718510 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfontanellar contrast-enhanced ultrasound (T-CEUS) during REEEA
Number of subjects: 9
Study 34718636 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher antibodies to Ae. aegypti salivary proteins
Number of subjects: 771
Study 34718665 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum bile acid (sBA) profiles measured by tandem MS at ages 3-6 and 9 months
Number of subjects: 365
Study 34718665 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum glycocholic acid (GCA)
Number of subjects: 365
Study 34718665 — intervention group
Group type: EXPERIMENTAL
Intervention: Proportion of GCA
Number of subjects: 365
Study 34718665 — intervention group
Group type: EXPERIMENTAL
Intervention: Bile acid composition
Number of subjects: 365
Study 34718665 — intervention group
Group type: EXPERIMENTAL
Intervention: Restoration of intestinal BA homeostasis
Number of subjects: 365
Study 34718665 — intervention group
Group type: COMPARATOR
Intervention: Well-nourished local children
Number of subjects: 365
Study 34718764 — intervention group
Group type: EXPERIMENTAL
Intervention: Social support
Number of subjects: 213
Study 34718764 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient activation
Number of subjects: 213
Study 34718774 — intervention group
Group type: EXPERIMENTAL
Intervention: [18F]FDG PET
Number of subjects: 14
Study 34718774 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI
Number of subjects: 14
Study 34718774 — intervention group
Group type: COMPARATOR
Intervention: [18F]FDG uptake
Number of subjects: 14
Study 34718859 — intervention group
Group type: EXPERIMENTAL
Intervention: High-LA diet (30, 40, or 50 ml of sunflower oil daily for 4 weeks)
Number of subjects: 59
Study 34718859 — intervention group
Group type: EXPERIMENTAL
Intervention: High-LA diet (30, 40, or 50 ml of sunflower oil daily for 4 weeks) in FADS1 rs174550-CC genotype
Number of subjects: 59
Study 34718884 — intervention group
Group type: EXPERIMENTAL
Intervention: NOAC (non-vitamin K-dependent oral antagonists)
Number of subjects: 1080
Study 34718884 — intervention group
Group type: EXPERIMENTAL
Intervention: In-hospital treatment after stroke
Number of subjects: 1080